Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$3.87 +10.3%	$2.56	$1.14 ▼ $7.20	$210.23M	0.68	834,192 shs	1.96 million shs
AVTE Aerovate Therapeutics	$10.51 +0.3%	$20.41	$48.48 ▼ $105.00	$304.63M	0.95	13,616 shs	271,204 shs
ERAS Erasca	$1.26 -8.7%	$1.38	$1.01 ▼ $3.45	$390.94M	1.09	1.73 million shs	1.27 million shs
QURE uniQure	$14.23 -0.7%	$14.51	$3.73 ▼ $19.18	$784.93M	0.08	1.95 million shs	904,318 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	+10.26%	+22.08%	+75.91%	-41.98%	+19.08%
AVTE Aerovate Therapeutics	+0.29%	+11.69%	+49.50%	-88.13%	-79.15%
ERAS Erasca	-8.70%	-10.00%	+16.67%	-17.11%	-42.73%
QURE uniQure	-0.70%	-5.76%	-8.19%	+14.11%	+223.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALDX Aldeyra Therapeutics	2.7635 of 5 stars	3.5	3.0	0.0	0.0	2.7	1.7	0.6
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	2.8299 of 5 stars	3.5	0.0	0.0	0.0	3.8	2.5	1.3
QURE uniQure	1.961 of 5 stars	3.5	1.0	0.0	0.0	1.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	3.00	Buy	$9.50	145.48% Upside
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
ERAS Erasca	3.00	Buy	$4.57	262.81% Upside
QURE uniQure	2.91	Moderate Buy	$37.82	165.76% Upside

Current Analyst Ratings Breakdown

Latest AVTE, ALDX, ERAS, and QURE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00
5/29/2025	QURE uniQure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00
5/19/2025	ALDX Aldeyra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/19/2025	QURE uniQure	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	ERAS Erasca	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$3.00
5/12/2025	QURE uniQure	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/12/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
5/6/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/30/2025	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
4/21/2025	QURE uniQure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
4/7/2025	ALDX Aldeyra Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $9.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$1.19 per share	N/A
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	$1.50 per share	N/A
QURE uniQure	$27.12M	28.74	N/A	N/A	($0.14) per share	-101.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$55.85M	-$0.97	N/A	N/A	N/A	N/A	-72.58%	-52.32%	7/30/2025 (Estimated)
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	8/11/2025 (Estimated)
ERAS Erasca	-$161.65M	-$0.62	N/A	N/A	N/A	N/A	-36.56%	-31.08%	8/11/2025 (Estimated)
QURE uniQure	-$239.56M	-$4.39	N/A	N/A	N/A	-1,077.05%	-483.87%	-34.28%	8/7/2025 (Estimated)

Latest AVTE, ALDX, ERAS, and QURE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ALDX Aldeyra Therapeutics	-$0.25	-$0.17	+$0.08	-$0.17	($0.80) million	N/A
5/13/2025	Q1 2025	ERAS Erasca	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
5/9/2025	Q1 2025	QURE uniQure	-$1.07	-$0.82	+$0.25	-$0.82	$5.93 million	$1.57 million
4/25/2025	Q4 2024	AVTE Aerovate Therapeutics	-$10.50	-$3.15	+$7.35	-$0.09	N/A	N/A
3/27/2025	Q4 2024	AVTE Aerovate Therapeutics	-$6.65	-$6.65	N/A	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A

Latest AVTE, ALDX, ERAS, and QURE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/9/2025	AVTE Aerovate Therapeutics		$84.00		4/29/2025	4/25/2025	4/28/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	0.24	6.49	6.49
AVTE Aerovate Therapeutics	N/A	8.78	8.78
ERAS Erasca	N/A	12.35	12.35
QURE uniQure	1.53	11.99	11.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
AVTE Aerovate Therapeutics	N/A
ERAS Erasca	67.78%
QURE uniQure	78.83%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	9.60%
AVTE Aerovate Therapeutics	24.90%
ERAS Erasca	14.40%
QURE uniQure	4.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	15	59.90 million	54.15 million	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
ERAS Erasca	120	283.29 million	242.49 million	Optionable
QURE uniQure	500	54.78 million	52.15 million	Optionable

AVTE, ALDX, ERAS, and QURE Headlines

Recent News About These Companies

uniQure (NASDAQ:QURE) Share Price Passes Below Fifty Day Moving Average on Insider Selling

June 25 at 2:19 AM | americanbankingnews.com

uniQure: Price And Value Have Caught Up

June 17, 2025 | seekingalpha.com

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

June 11, 2025 | globenewswire.com

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

June 2, 2025 | globenewswire.com

3 Top Genomics Stocks to Add to Your Portfolio in 2025

May 21, 2025 | zacks.com

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

May 14, 2025 | zacks.com

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

May 9, 2025 | zacks.com

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

May 9, 2025 | globenewswire.com

uniQure to Announce First Quarter 2025 Financial Results

May 5, 2025 | globenewswire.com

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?

April 21, 2025 | zacks.com

uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold

April 21, 2025 | seekingalpha.com

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130

April 21, 2025 | seekingalpha.com

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

April 17, 2025 | globenewswire.com

UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates

February 27, 2025 | zacks.com

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

February 27, 2025 | globenewswire.com

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

February 7, 2025 | benzinga.com

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

February 7, 2025 | prnewswire.com

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

February 3, 2025 | globenewswire.com

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

January 30, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTE, ALDX, ERAS, and QURE Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$3.87 +0.36 (+10.26%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$3.88 +0.00 (+0.13%)

As of 04:37 AM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Aerovate Therapeutics NASDAQ:AVTE

$10.51 +0.03 (+0.29%)

As of 06/25/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Erasca NASDAQ:ERAS

$1.26 -0.12 (-8.70%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.25 -0.01 (-0.40%)

As of 06/26/2025 07:32 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

uniQure NASDAQ:QURE

$14.23 -0.10 (-0.70%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$14.30 +0.07 (+0.49%)

As of 04:10 AM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time